Patents

US 12383522 B2: Baclofen formulations and methods of minimizing patient exposure to metabolite variations

Granted
2025-08-12
Filed
2023-11-14 application 18508830
Type
Utility · 16 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.

Source: PVGPATDIS, file of 2026-04-10 (ipg250812.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
AMNEAL PHARMACEUTICALS LLC 33 patentsUS company or organizationBound Brook Junction, NJAMNEAL PHARMACEUTICALS LLC Federal lobbying client EXACT high confidence: identical full name and state
AMNEAL PHARMACEUTICALS, INC. SEC filer FUZZY low confidence: same name (legal endings aside), one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Leonard O'MahonyMullingar, IE12PVGPATDIS, file of 2026-04-10
Sharon HammGulf Pine, FL18PVGPATDIS, file of 2026-04-10
John DevaneDublin, IE16PVGPATDIS, file of 2026-04-10
David PenakeAtlanta, GA21PVGPATDIS, file of 2026-04-10
Wolfgang MohrFreiburg (Elbe), DE7PVGPATDIS, file of 2026-04-10
Manuel WeinheimerNeustadt an der Weinstraße, DE6PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/197PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2025-09-22Security interest Security interest
Security interest
AMNEAL PHARMACEUTICALS LLC signed 2025-08-01
IMPAX LABORATORIES, LLC signed 2025-08-01
TRUIST BANK, AS COLLATERAL AGENT ATLANTA, GA72321/852PASDL, file of 2026-10-25
2025-08-01Security interest Security interest
Patent security agreement
AMNEAL PHARMACEUTICALS LLC signed 2025-08-01
IMPAX LABORATORIES, LLC signed 2025-08-01
GEMINI LABORATORIES, LLC signed 2025-08-01
WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT WILMINGTON, DE72312/127PASDL, file of 2026-10-25
2025-08-01Security interest Security interest
Security interest
AMNEAL PHARMACEUTICALS LLC signed 2025-08-01
IMPAX LABORATORIES, LLC signed 2025-08-01
JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT CHICAGO, IL71905/166PASDL, file of 2026-10-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.